Approval · Notice of Compliance 30679 · 2023
MINT-BUSPIRONE: Notice of Compliance 30679
Issued May 9, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 30679
- Date
- May 9, 2023
- Company
- Mint Pharmaceuticals IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Labelling Only
- Reason
- Update to the Product Monograph
- Canadian reference product
- APO-BUSPIRONE (Apotex Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MINT-BUSPIRONE | Not yet assigned | — |
Medicinal ingredients
- BUSPIRONE HCL 10 MG per TAB